Mass screening adoption (blood-based cancer tests, AI diagnostics) will outpace follow-up infrastructure, resulting in worsening follow-up completion rates relative to test volume, increased litigation, and no net improvement in outcomes for flagged patients within the next 18 months.
medium confidence
Key findings
Policy momentum, legal liability pressure, and AI-enabled follow-up tools create strong incentives for improvement, though systemic adherence gaps persist.
The fundamental bottleneck is structural — cheap, scalable front-end screening generates exponentially more flags than the slow-to-build, expensive, workforce-constrained follow-up system (endoscopy suites, specialists, surgical capacity) can absorb, and neither pending legislation nor legal...
Based on today's data, "test followup" predominantly refers to the critical second step in a multi-stage process, a pattern with deep historical
Perspectives
The risk perspectivemedium
The fundamental bottleneck is structural — cheap, scalable front-end screening generates exponentially more flags than the slow-to-build, expensive, workforce-constrained follow-up system (endoscopy suites, specialists, surgical capacity) can absorb, and neither pending legislation nor legal pressure changes capacity on a relevant timeline.
The historical perspectivemedium
Based on today's data, "test followup" predominantly refers to the critical second step in a multi-stage process, a pattern with deep historical
The quantitative perspectivehigh
Policy momentum, legal liability pressure, and AI-enabled follow-up tools create strong incentives for improvement, though systemic adherence gaps persist.